All In Biotech

Drug Trial Radar · NCT00359021

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

An Open-label Trial With TMC125 as Part of an ART Including TMC114/Rtv and an Investigator-selected OBR in HIV-1 Infected Subjects Who Participated in a DUET Phase III Trial (TMC125-C206 or TMC125-C216).

Last checked: Nov 19, 2026Latest source record: May 16, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

503

Actual

Start

Jun 2006

Primary completion

Jan 2012

Study completion Jan 2012

Sponsor

Sponsor type
Industry
First posted
Aug 1, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate the long-term safety and tolerability of TMC125 200 mg twice daily as part of an antiretroviral therapy including TMC114/rtv and an investigator selected optimized background in HIV-1 infected patients who have participated in a DUET trial (TMC125-C206 or TMC125 C216) and have met the definition of virologic failure at Week 24 or later in these trials.

Conditions

  • HIV-1

Interventions

  • TMC125Drug

    200 mg twice daily until commercially available

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Participants Experiencing Adverse EventsTime frame: 1 week to 180 weeks, with a median of 62 weeks

Locations

72 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Beverly Hills, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Palm Springs, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Denver, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Fort Laudersale, Florida

  • Site not named

    Miami, Florida

  • Site not named

    North Miami Beach, Florida

  • Site not named

    Safety Harbor, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Boston, Massachusetts

  • Site not named

    Camden, New Jersey

  • Site not named

    Newark, New Jersey

  • Site not named

    New York, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Austin, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Longview, Texas

  • Site not named

    Annandale, Virginia

  • Site not named

    Seattle, Washington

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Neuquén, Argentina

  • Site not named

    San Juan Bautista, Argentina

  • Site not named

    Darlinghurst, Australia

  • Site not named

    Antwerp, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Curitiba, Brazil

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.